DUBLIN--(BUSINESS WIRE)--The "Global Tardive Dyskinesia Treatment Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
The Global Tardive Dyskinesia Treatment Market is anticipated to grow at a CAGR of 4.44% during the period 2019-2023.
One trend affecting this market is the increasing R&D on VMAT2 inhibitors. Most of the established companies in the global tardive dyskinesia treatment market are focused on developing novel therapeutics by researching extensively on VMAT2 inhibitors.
According to the report, one driver influencing this market is the increasing use of antipsychotic drugs across the globe. There has been a significant rise in the administration of antipsychotic drugs which is resulting in growing prevalence of tardive dyskinesia.
Further, the report states that one challenge affecting this market is the lack of awareness. The growth of the market is impeded by the lack of awareness about the disorder in many regions.
Key Vendors
- F. Hoffmann-La Roche
- Merck
- Neurocrine Biosciences
- Novartis
- Teva Pharmaceutical
Key Topics Covered
1. Executive Summary
2. Scope of the Report
3. Market Landscape
4. Market Sizing
5. Five Forces Analysis
6. Market Segmentation by Product
7. Customer Landscape
8. Geographic Landscape
9. Decision Framework
10. Drivers and Challenges
11. Market Trends
12. Vendor Landscape
13. Vendor Analysis
For more information about this report visit https://www.researchandmarkets.com/research/q47crj/global_tardive?w=4
